Cullen Investment Group LTD. Buys 454 Shares of DexCom, Inc. (NASDAQ:DXCM)

Cullen Investment Group LTD. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,888 shares of the medical device company’s stock after acquiring an additional 454 shares during the quarter. Cullen Investment Group LTD.’s holdings in DexCom were worth $730,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New Hampshire bought a new stake in DexCom during the first quarter worth $1,508,000. Waters Parkerson & CO. LLC boosted its holdings in shares of DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after buying an additional 10,892 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares during the last quarter. Mattson Financial Services LLC bought a new position in DexCom during the second quarter valued at about $2,003,000. Finally, Los Angeles Capital Management LLC increased its holdings in DexCom by 62.5% during the first quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock worth $49,520,000 after buying an additional 137,336 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM traded up $2.43 during trading hours on Friday, reaching $68.11. 6,336,526 shares of the stock traded hands, compared to its average volume of 3,819,679. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a market cap of $27.09 billion, a P/E ratio of 43.94, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company’s 50-day moving average price is $70.19 and its two-hundred day moving average price is $105.15.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.34 EPS. On average, analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock worth $126,390 in the last quarter. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research analyst reports. Robert W. Baird raised their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $145.00 to $75.00 in a research note on Friday, July 26th. Baird R W downgraded DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Morgan Stanley lowered their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.